Reneuron Group (RENE)

 

RENE Share PerformanceMore

52 week high3.8700 15/03/16
52 week low2.2500 04/11/16
52 week change -0.0060 (-0.21%)
4 week volume79,984,080 09/11/16

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

ReNeuron widens H1 pretax loss

ReNeuron has widened its H1 pretax loss to 8.6m, from a loss of 5.2m. Revenue was 22,000, from 11,000. Research and develo...

ReNeuron reports positive results in Phase II Stroke Trial

ReNeuron Group announces positive data from its Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for s...

Interim Results

RNS Number: 8915Q ReNeuron Group plc 05 December 2016 Details are given below of an analyst meeting and webcast at 9.00am this morning 5 December 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Interim Results for the six months ended 30 September 2016 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the develop...

Reports Positive Results in Phase II Stroke Trial

RNS Number: 8916Q ReNeuron Group plc 05 December 2016 5 December 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Reports positive results in Phase II stroke trial ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce positive data from the Company's Phase II ...

Notification of Interim Results

RNS Number: 0361P ReNeuron Group plc 14 November 2016 14 November 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Interim Results ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , intends to announce its interim results for the six months ended 30 September...

ReNeuron Group Plc to present at the Shares Investor Evening in London on 27th October 2016

Michael Hunt, CFO of ReNeuron Group (RENE) (LSE:RENE) will be giving a briefing at the Shares Investor Evening on...

Notification of Major Interest in Shares

RNS Number: 7883L ReNeuron Group plc 05 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ReNeuron Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisi...

Block Listing Review and Total Voting Rights

RNS Number: 5877K ReNeuron Group plc 22 September 2016 22 September 2016 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Block Listing Review and Total Voting Rights ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six...

Fundamental DataMore

EPS-0.4
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
05/08/2016
ReNeuron has announced the publication of long-term Phase I stroke clinical trial (PISCES-I) data in The Lancet. The data indicate improvements in neurological status and limb function compared with...
edison investment research
ReNeuron Group plc
27/07/2016
Investor focus is currently on the readout of ReNeuron’s Phase II stroke disability study with its CTX cells, due in Q416. Alongside this there are a number of other data readouts and progression of...
edison investment research
ReNeuron Group plc
24/03/2016
ReNeuron has treated the first patient in its US Phase I/II clinical trial with its cell therapy candidate for the blindness-causing disease retinitis pigmentosa (RP). This is a significant step...

Latest discussion posts More

  • Re: MotleyFool on Reneuron

    Not much substance with this article by Peter Stephens who is by admission a share holder in AstraZenica ... basically on a day that we have encouraging news to say AstraZenica ...
    5-Dec-2016
    omg
  • Sharecast article

    eNeuron's first half revenues supported by new drug developments Mon, 5th Dec 2016 11:06 (ShareCast News) - ReNeuron, an AIM-listed UK based developer of cell-based ...
    5-Dec-2016
    fredd1eboy
  • Re: MotleyFool on Reneuron

    Here's the link: http://www.fool.co.uk/investing/2016/12/05/is-reneuron-group-plc-a-better-buy-than-astrazeneca-plc/
    5-Dec-2016
    Vach

Users' HoldingsMore

Users who hold Reneuron Group also hold..
LLOYDS GRP.17%
BARCLAYS13%
BP12%
ROCKHOPPER11%
ROYAL BANK SCOT11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE